Chat with Filing

Ask questions about this document

Please log in or register to use the chat feature. Please register first.

ER - BRAIN Biotech AG reports preliminary Q2 figures and forecasts a more conservative development for the second half of the fiscal year 2024/25

Company: BRAIN Biotech AG Date: 2025-04-30 Language: English Register to download

Loading document preview...

Document Preview Not Available

The file type (.html) cannot be displayed directly here.

Open Original File

Error loading document preview. Please try the 'Open Original File' link.

You're One Click Away From The Full Filing

Instantly access this document—and 2.8M more—for free. Select your preferred method:

Continue with Google Continue with Microsoft Continue with Facebook Continue with Amazon

 News Details 

Ad-hoc | 30 April 2025 17:54

#   

BRAIN Biotech AG reports preliminary Q2 figures and forecasts a more conservative development for the second half of the fiscal year 2024/25

BRAIN Biotech AG / Key word(s): Preliminary Results/Change in Forecast  

BRAIN Biotech AG reports preliminary Q2 figures and forecasts a more conservative development for the second half of the fiscal year 2024/25  

  

30-Apr-2025 / 17:54 CET/CEST  

Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News – a service of EQS Group.  

The issuer is solely responsible for the content of this announcement.  

  

- - -

**BRAIN Biotech AG reports preliminary Q2 figures and forecasts a more conservative development for the second half of the fiscal year 2024/25**

**Zwingenberg, Germany, 30 April 2024** – BRAIN Biotech AG (ISIN DE0005203947; “ **BRAIN** ” or “ **Company** ”) today reports preliminary Q2 figures for the financial year 2024/25 with Q2 revenues of EUR 12.12 million and an adjusted EBITDA of minus EUR 0.36 million. The publication of the comprehensive half year reporting for 31 March 2025 (6M) and the analyst call will take place as previously scheduled on May 28 th , 2025.

Due to the overall weaker economic environment and strong USD currency fluctuations the Company now forecasts full-year 2024/25 revenues for the core segment BRAINBiocatalysts to be around the level of last year and therefore below the original guidance. The guidance for the adjusted EBITDA margin in the segment BRAINBiocatalysts and the guidance for the segment BRAINBioIncubator remains unchanged.

Notifying person:

Martina Schuster  

BRAIN Biotech AG  

– Investor Relations –  

Darmstädter Str. 34-36  

64673 Zwingenberg  

Deutschland

www.brain-biotech-group.com

Investor Relations Office  

Tel.: +49-(0)-6251-9331-0  

Fax: +49-(0)-6251-9331-11  

E-Mail: ir@brain-biotech.com

  

  

End of Inside Information  

- - -

30-Apr-2025 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.  

Archive at www.eqs-news.com  

- - -

|     |     |
| --- | --- |
| Language: | English |
| Company: | BRAIN Biotech AG |
|     | Darmstädter Straße 34-36 |
|     | 64673 Zwingenberg |
|     | Germany |
| Phone: | +49 (0) 62 51 / 9331-0 |
| Fax: | +49 (0) 62 51 / 9331-11 |
| E-mail: | ir@brain-biotech.com |
| Internet: | www.brain-biotech.com |
| ISIN: | DE0005203947 |
| WKN: | 520394 |
| Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange |
| EQS News ID: | 2128270 |

  

|     |     |
| --- | --- |
|     |     |
| End of Announcement | EQS News Service |

- - -

2128270  30-Apr-2025 CET/CEST

![](https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=2128270&application_name=news&site_id=airport_aws~~~7cc68db1-74de-43c8-af69-2ae0a97efdc3)

Unlock Europe's Largest Financial Database—Free

Get instant access to over 2.8M filings from 8,970 companies across 44 markets. No cost. No hassle. Just results.